• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • NORTH AMERICA EDITION
      Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • NORTH AMERICA EDITION
      North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Helix BioPharma Gets FDA Approval to Accelerate Dose Escalation in Trial

    Bryan Mc Govern
    Sep. 28, 2017 09:55AM PST
    Pharmaceutical Investing

    Helix BioPharma announced that the FDA approved an amendment to their phase I study, protocol LDOS001, to accelerate the dose escalation phase of the study.

    Helix BioPharma (TSX:HBP) announced that the US Food and Drug Administration (FDA) approved an amendment to their phase I study, protocol LDOS001, to accelerate the dose escalation phase of the study.
    As quoted in the press release:

    In order to maximize the number of patients receiving a potentially active dose of L-DOS47, the study will implement an accelerated dose design up to 6µg/kg followed by a standard 3+3 design for the final two dosing cohorts, 9 and 12 µg/kg, respectively.
    “This was a significant achievement in the advancement of the study,” said Steve Demas, Chief Operating Officer of Helix. “We will be able to move more rapidly through the escalation phase to doses of L-DOS47 that exhibited the best patient responses in the Phase I monotherapy study (“LDOS002″), recently completed in Poland. We are also planning on opening additional centers to further accelerate the completion of the study.”

    Click here to read the full press release.

    Source: www.marketwired.com

    pharmaceutical investinghelix biopharmachief operating officerphase i studyfood and drug administration
    The Conversation (0)

    Go Deeper

    AI Powered
    A hand holding a double helix.

    Top 5 NASDAQ Genetics Stocks (Updated December 2023)

    Key Stock Catalysts in the FDA Drug Application Process

    Key Stock Catalysts in the FDA Drug Application Process

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Cardiol Therapeutics

    CRDL:CA
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×